Clinical Programs

The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria-targeting cardiolipin peroxidation inhibitors. Visomitin® has reached Phase III in the U.S. for dry eye disease. Visomitin’s mechanism of action addresses the most important clinical needs in dry eye disease: tear quality, cornea/conjunctiva healing rate and inflammation.

With an established safety profile and extensive mechanistic evidence, Mitotech is preparing for the clinical development of Visotmitin in other ophthalmic indications, notably glaucoma, Leber’s Hereditary Optic Neuropathy (LHON), dry AMD, and uveitis.